Literature DB >> 30566832

DARK Classics in Chemical Neuroscience: Atropine, Scopolamine, and Other Anticholinergic Deliriant Hallucinogens.

Anton M Lakstygal1, Tatiana O Kolesnikova2, Sergey L Khatsko2, Konstantin N Zabegalov2, Andrey D Volgin3, Konstantin A Demin3,4, Vadim A Shevyrin2, Edina A Wappler-Guzzetta5, Allan V Kalueff6,7,8,9,10,11.   

Abstract

Anticholinergic drugs based on tropane alkaloids, including atropine, scopolamine, and hyoscyamine, have been used for various medicinal and toxic purposes for millennia. These drugs are competitive antagonists of acetylcholine muscarinic (M-) receptors that potently modulate the central nervous system (CNS). Currently used clinically to treat vomiting, nausea, and bradycardia, as well as alongside other anesthetics to avoid vagal inhibition, these drugs also evoke potent psychotropic effects, including characteristic delirium-like states with hallucinations, altered mood, and cognitive deficits. Given the growing clinical importance of anti-M deliriant hallucinogens, here we discuss their use and abuse, clinical importance, and the growing value in preclinical (experimental) animal models relevant to modeling CNS functions and dysfunctions.

Entities:  

Keywords:  Cholinergic system; antimuscarinic effects; atropine; deliriant drugs; hallucinogens; scopolamine

Mesh:

Substances:

Year:  2019        PMID: 30566832     DOI: 10.1021/acschemneuro.8b00615

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  9 in total

1.  Structure-Activity Relationship Study of Psychostimulant Synthetic Cathinones Reveals Nanomolar Antagonist Potency of α-Pyrrolidinohexiophenone at Human Muscarinic M2 Receptors.

Authors:  Yiming Chen; Clinton E Canal
Journal:  ACS Chem Neurosci       Date:  2020-03-03       Impact factor: 4.418

2.  A Selective M1 and M3 Receptor Antagonist, Penehyclidine Hydrochloride, Exerts Antidepressant-Like Effect in Mice.

Authors:  Xiaojing Sun; Congcong Sun; Lingyan Zhai; Wei Dong
Journal:  Neurochem Res       Date:  2019-10-12       Impact factor: 3.996

Review 3.  Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.

Authors:  Chad R Johnson; Brian D Kangas; Emily M Jutkiewicz; Jack Bergman; Andrew Coop
Journal:  Biomedicines       Date:  2022-02-07

4.  Hallucinogenic Persisting Perception Disorder: A Case Series and Review of the Literature.

Authors:  Hannah Ford; Clare L Fraser; Emma Solly; Meaghan Clough; Joanne Fielding; Owen White; Anneke Van Der Walt
Journal:  Front Neurol       Date:  2022-05-06       Impact factor: 4.086

5.  Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition.

Authors:  Chad R Johnson; Brian D Kangas; Emily M Jutkiewicz; Gail Winger; Jack Bergman; Andrew Coop; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2021-03-12       Impact factor: 4.402

Review 6.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

7.  Datura genome reveals duplications of psychoactive alkaloid biosynthetic genes and high mutation rate following tissue culture.

Authors:  Alex Rajewski; Derreck Carter-House; Jason Stajich; Amy Litt
Journal:  BMC Genomics       Date:  2021-03-22       Impact factor: 3.969

Review 8.  QR code model: a new possibility for GPCR phosphorylation recognition.

Authors:  Hao Chen; Suli Zhang; Xi Zhang; Huirong Liu
Journal:  Cell Commun Signal       Date:  2022-03-02       Impact factor: 5.712

Review 9.  Beauty of the beast: anticholinergic tropane alkaloids in therapeutics.

Authors:  Kyu Hwan Shim; Min Ju Kang; Niti Sharma; Seong Soo A An
Journal:  Nat Prod Bioprospect       Date:  2022-09-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.